Trials / Completed
CompletedNCT02922231
Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 57 (actual)
- Sponsor
- Baxalta now part of Shire · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Primary: To characterize the safety of RIXUBIS when used under normal clinical care in South Korea. Secondary: To describe hemostatic effectiveness in subjects receiving RIXUBIS under normal clinical care in South Korea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | RIXUBIS | Recombinant Factor IX (rFIX) for intravenous use |
Timeline
- Start date
- 2017-01-06
- Primary completion
- 2019-04-04
- Completion
- 2019-04-04
- First posted
- 2016-10-04
- Last updated
- 2021-05-05
Locations
5 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02922231. Inclusion in this directory is not an endorsement.